ALDX
Aldeyra Therapeutics, Inc.
1.20$
-1.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 99.7% | 99.6% | 99.8% | 99.5% | 99.7% | 99.5% | 99.6% | 99.8% | 99.9% | 99.7% | 99.5% | 99.6% | |
| 97.0% | 51.9% | 47.7% | 45.3% | 49.8% | 58.8% | 93.4% | 98.6% | 79.7% | 96.3% | 52.1% | 97.2% | |
| 97.0% | 97.8% | 98.9% | 97.2% | 98.4% | 97.1% | 93.4% | 98.6% | 96.1% | 96.3% | 96.7% | 97.2% | |
| – | – | – | 40.7% | 46.3% | 37.1% | 30.0% | 0.0% | 1.8% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | -37.1% | -24.2% | -53.6% | -1.8% | – | – | – | |
| 0.1% | 0.3% | 0.2% | 0.1% | 0.2% | 0.2% | 0.1% | 0.0% | 0.0% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 28.5% | 11.8% | 14.0% | 10.4% | 8.9% | 36.3% | 28.6% | 11.8% | 16.7% | 19.2% | 32.1% | 38.6% | |
| 15.1% | 7.5% | 9.1% | 7.6% | 8.9% | 17.1% | 14.9% | 5.0% | 8.5% | 15.0% | 17.8% | 38.6% | |
| 0.9% | 0.3% | 0.3% | 0.3% | – | 0.3% | 4.7% | 0.1% | 0.6% | 10.4% | 0.3% | 21.6% | |
| 3.9% | 3.0% | 1.1% | 2.3% | 3.2% | 1.1% | 0.5% | 0.4% | 0.1% | 0.9% | 0.2% | 0.2% | |
| 13.4% | 4.3% | 4.9% | 2.8% | – | 19.2% | 13.7% | 6.7% | 8.2% | – | 14.3% | – | |
| 71.5% | 88.2% | 86.0% | 89.6% | 91.1% | 63.7% | 71.4% | 88.2% | 83.3% | 80.8% | 67.9% | 61.4% | |
| -529.3% | -207.8% | -306.9% | -225.6% | -145.7% | -264.0% | -284.2% | -126.4% | -196.8% | -265.8% | -430.3% | -671.6% | |
| 43.8% | 30.6% | 45.1% | 36.0% | 22.8% | 35.9% | 40.7% | 23.2% | 32.2% | 39.7% | 56.9% | 83.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.